A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...
Lupron and other LHRH agonists are forms of hormone-blocking therapy. For people with prostate cancer, hormone-blocking therapy aims to reduce testosterone levels in the body. Male hormones ...
Since the existence of the oligometastatic disease state was posited three decades ago,1 there has been interest in ...
The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence ...
Patients with metastatic prostate cancer showed similar prostate-specific antigen ... substance that prevent the making of sex hormones. Androgen deprivation therapy: treatment to reduce the level of ...
Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...
Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...
MedPage Today on MSN6d
Study of Oligorecurrent Prostate Cancer Finds Winning CombinationA short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of ...
In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...
Among menopausal women, hormone therapy use and duration were not associated with brain malignancy risk, although researchers cautioned that more research is needed, according to findings published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback